McDermott Will & Emery Life Sciences Private Equity Dealmaking Symposium
Opportunities and challenges for those investing and operating in the life sciences industry
Date : October 10, 2012 Time : 11:00 AM CST
Join West Monroe Partners at McDermott Will & Emery's 2012 Life Sciences Private Equity Dealmaking Symposium.

This inaugural event will focus on the opportunities and challenges for those investing and operating in the multibillion dollar life sciences industry.  A seasoned panel of private equity, pharmaceutical, biotechnology, medical products and services leaders will provide insight and guidance into how to address the ever-changing landscape.  Symposium attendees will include private equity managing directors, investment bankers and C-level executives from medical device, pharmaceutical, diagnostics and other medical products industry participants.

West Monroe will be speaking on the panel "Executing and Financing Carve-Outs from Life Sciences Companies." Carve-outs are becoming increasingly common as life sciences companies examine core assets and refocus on best practices in preparing a division or product line for divestiture. The panel will discuss how to assess transition services, intellectual property, accounting and staffing issues as well as how lenders assess a carve-out transaction. Access the full agenda here.

The event is being held at the JW Marriott Chicago.

West Monroe Insights
Transforming from the Inside Out: Digital in Energy & Utilities
View More
Related Insights
How pharma companies can facilitate higher quality patient care at a lower cost.
Date : May 19, 2017
Pharmaceutical companies that have adopted a patient-centric approach have seen significant benefits in the form of greater patient adherence to medication, more consistent customer engagement, and overall improvements in the efficiency of their medical information and pharmacovigilance operations.
Natural Language Generation Goes to Work
Date : January 24, 2017

Natural Language Generation (NLG) is a form of artificial intelligence (AI) which takes an input of data and produces a narrative similar to how a human would interpret the data. NLG technology can be very transformative when used in business situations, especially in industries that are heavily dependent on generating text summaries based on straightforward conclusions drawn from structured data and that lack the capital to support a large workforce.

Join West Monroe's Anthony Chambers for a webcast in partnership with Mergermarket, Citrix and BioPharm Insight
Date : June 10, 2016 Time : 02:00 PM EST
Experts speculate speculation that a raft of pharma consolidation can be expected this year as companies look to cut costs. Will this be the case? How can pharma companies deal with pressure from PBMs, insurers and the public?
New York